About TFBS About TFBS
About TFBS
CDMO CDMO
CDMO
Testing Testing
Testing
The Japan Times-Cost-effective and reliable services for GMP
The Japan Times-Cost-effective and reliable services for GMP

TFBS Bioscience and Japan Tissue Engineering Collaborate on Feasibility Study for Commercialization of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan ～Collaboration under the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy"～

2026-08-21

TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") and Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori City, Aichi Prefecture, Japan; hereinafter "J-TEC") have agreed to collaborate on a study regarding the commercialization of J-TEC's regenerative medicine products (such as autologous cultured epidermis) currently marketed in Japan for the Taiwan market.

This partnership is being conducted as part of the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy" program. Under this program, J-TEC’s application titled "Study on the Licensing-out of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan and Other Regions" was officially selected under a public call by the Ministry of Economy, Trade and Industry (METI). TFBS will participate in this project as a local partner for market research and business feasibility assessment, collaborating to evaluate the expansion potential of J-TEC’s regenerative medicine products in Taiwan.

For details and an overview of this subsidized project, please refer to the press release issued by J-TEC.

Group photo of representatives from both companies
▲ Group photo of representatives from both companies at TFBS Bioscience Headquarters (Taiwan)
(From left: Mitsuo, BD Director of TFBS; Dr. Yamada, President and CEO of J-TEC; Huang, Advisor of TFBS; Mr. Sakakibara, Executive Officer of J-TEC; Mr. Horiuchi, Sales Director of J-TEC; Lo, BD Director of TFBS; Wei, Senior Technical Manager of TFBS)

■ About TFBS Bioscience Inc. (TFBS)

TFBS Bioscience Inc. was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus. With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy. For more information, please visit www.tfbsbio.com.

■ About Japan Tissue Engineering Co., Ltd. (J-TEC)

J-TEC is a leading regenerative medicine manufacturer driven by the vision of "Creating a Future for Regenerative Medicine," and has been a member of the Teijin Group since March 2021. As a pioneer in Japan's regenerative medicine industry, J-TEC achieved the country's first-ever regulatory approval for a regenerative medicine product in October 2007 with its autologous cultured epidermis "JACE®." J-TEC currently markets five tissue-engineered products, including cultured epidermis, cartilage, and corneal epithelium.

■ Contact Information

TFBS Bioscience, Inc.
E-mail: service@tfbsbio.com

    Share :

    BACK